X
[{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara\u00ae at Week 16 in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Shows Positive Phase 3b Results Against Cosentyx","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Achieves Important Regulatory Milestone for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira\u00ae in Moderate-to-Severe Psoriasis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\"The New England Journal of Medicine\" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on U.S. FDA Review of Biologics License Application (BLA) for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Ajinomoto Bio-Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, acceptance EU Regulatory Filing for Bimekizumab for the Treatment of Hidradenitis Suppurativa.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: Bimzelx
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 18, 2023
Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes, it is being investigated for moderate to severe plaque psoriasis in adults.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: Bimzelx
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 18, 2023
Details:
Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: Bimzelx
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 09, 2022
Details:
UCB4940 (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: UCB4940
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2022
Details:
Two manuscripts published back to back detail the full results from the BE RADIANT and BE SURE studies, comparing the efficacy and safety of bimekizumab to secukinumab and adalimumab, respectively
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: Bimzelx
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 23, 2021
Details:
This will include 11 e-posters and an oral presentation of late-breaking data from the Phase 3b BE RADIANT study evaluating the efficacy and safety of bimekizumab compared to secukinumab in the treatment of moderate to severe plaque psoriasis.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: Bimzelx
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 23, 2021
Details:
The data from the BE VIVID and BE READY studies demonstrated bimekizumab-treated patients achieved superior levels of skin clearance at week 16 compared to those who received placebo or Janssen’s Stelara (ustekinumab).
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: UCB4940
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 04, 2021
Details:
Aji Bio-Pharma will operate as a dual source of supply and provide drug product manufacturing services to Revance for the supply of DaxibotulinumtoxinA for Injection at the company's aseptic manufacturing facility in San Diego, California.
Lead Product(s):
Daxibotulinumtoxin A
Therapeutic Area: Dermatology
Product Name: DaxibotulinumtoxinA
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Revance Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
December 22, 2020
Details:
Data from the Phase 3 BE SURE study demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved significantly higher PASI 90 and PASI 100 skin clearance rates, compared to Humira®, at week 16.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: UCB4940
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 31, 2020
Details:
This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara[®] (ustekinumab) and Humira[®] (adalimumab) in achieving skin clearance at week 16.
Lead Product(s):
Bimekizumab
Therapeutic Area: Dermatology
Product Name: UCB4940
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 22, 2020